A pilot study to identify the longitudinal serum metabolite profiles to predict the development of hyperuricemia in essential hypertension.

Heru Zhao, Yin Zhang, Bin Liu, Lulu Zhang, Mei Bao, Li Li, Ning Zhao, Muhummad Hussain, Yuexi Wang, Jianfeng Yi, Peng Chen, Cheng Lu

Journal: Clinica chimica acta; international journal of clinical chemistry 2021;510():466-474

PMID: 32771482

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND

Essential hypertension (EHT) is the most prevalent chronic medical condition and a major risk factor for cardiovascular morbidity and mortality. EHT often progresses and combines with hyperuricemia (HU) in clinical cases, which increases organ damage in patients with EHT. We compared serum metabolites in EHT patients with EHT + HU patients and to find metabolic markers and related pathways in the progression of EHT to EHT + HU.

METHODS

A longitudinal study was carried out in 35 patients (initially EHT and EHT + HU one year later). With 10 metabolites in EHT + HU identified as potential biomarkers, linoleic acid metabolism, sphingolipid metabolism, steroid hormone biosynthesis, starch and sucrose metabolism and purine metabolism interacted with EHT + HU.

RESULTS

Distinct changes in the metabolomics profile of sera were observed among healthy controls (HC), EHT and EHT + HU groups. Uric acid (UA), L-lactic acid, and quinolinic acid may play important roles in the progression from EHT to EHT + HU. They were mainly involved in pyruvate metabolism, purine metabolism and nicotinate and nicotinamide metabolism pathways.

CONCLUSIONS

The continuous elevation of L-lactic acid and quinolinic acid might be useful for understanding the mechanisms of pathogenesis in EHT + HU and provide prospects for preventing the development of EHT and HU.

Address: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China; Key Laboratory for Research on Active Ingredients in Natural Medicine of Jiangxi Province, Yichun University, Yichun 336000, China.; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.; School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China.; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: [email protected].; Key Laboratory for Research on Active Ingredients in Natural Medicine of Jiangxi Province, Yichun University, Yichun 336000, China. Electronic address: [email protected].; Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Dongcheng District, Beijing 100700, China. Electronic address: [email protected].; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: [email protected].

DOI: 10.1016/j.cca.2020.08.002

Link outs

Free resources

Medical:

https://medlineplus.gov/highbloodpressure.html

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0009...

MeSH Terms: Essential Hypertension, Humans, Hypertension, Hyperuricemia, Longitudinal Studies, Pilot Projects, Uric Acid